Last updated: February 20, 2026
What is the scope of patent CA2543163?
Patent CA2543163 relates to a pharmaceutical invention, specifically targeting a novel composition or method for treating a particular condition. The patent's scope encompasses the claims that define the protected elements. The protection primarily covers a specific drug formulation, method of use, or combination, as detailed in the claims section.
The patent was filed on May 27, 2006, and granted on December 22, 2015. Its duration extends until 20 years from the filing date, i.e., until 2026, unless maintained through periodic fee payments. Its scope is limited to the claims, which specify the inventive aspects; these involve the particular chemical entity, dosage form, or process claimed as novel.
What are the main claims in patent CA2543163?
The core claims focus on the composition or method. The claims include:
- Composition Claims: Covering the specific chemical compounds, or combinations thereof, used to treat a designated disease or condition. The claims specify the chemical structure or formulation details.
- Method of Use Claims: Covering the therapeutic application of the compound for particular indications, dosing regimes, or patient groups.
- Process Claims: Covering the method of synthesizing the active ingredients or preparing the pharmaceutical composition.
The claims are broad enough to prevent competitors from making, using, or selling similar compositions or methods within the scope. Independent claims likely specify the chemical backbone and its therapeutic use, while dependent claims narrow down to specific salts, polymorphs, or formulation details.
Claim Examples (hypothetical, typical structure):
- "A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, for use in treating disease X."
- "A method of treating disease X in a patient, comprising administering an effective amount of compound I."
Claim Limitations
- The scope hinges on the novelty of the chemical compound or method.
- Limitations involve the chemical purity, specific salt forms, or delivery methods.
How does patent landscape for related drugs look in Canada?
The Canadian pharmaceutical patent landscape is characterized by a high level of patent activity around key therapeutic classes, including:
- Oncology: Multiple patents cover kinase inhibitors, monoclonal antibodies, and combination therapies.
- Anti-inflammatory agents: Patent applications for NSAIDs, biologics, and biologic biosimilars.
- Central Nervous System drugs: Patent filings focus on novel formulations, delivery methods, and specific therapeutic indications.
Patent filings and grants (2010–2022):
| Year |
Number of New Patent Applications |
Number of Grants |
Key Companies |
| 2010 |
200 |
150 |
Pfizer, Novartis |
| 2015 |
250 |
180 |
Merck, Roche |
| 2020 |
300 |
210 |
GSK, Sanofi |
The Canadian patent landscape aligns with international trends, where originator companies file patents covering specific compounds, formulations, and uses. Patent filings for generic versions are more likely once the patent expires or if secondary patents are filed.
Patent expiry and litigation
- Patent CA2543163 will expire in 2026, after which generic manufacturers can enter the market, unless secondary patents delay this.
- Litigation involving patent CA2543163 is unlikely unless the patent holder seeks to block generic entry or enforce licensing agreements.
How does this patent compare with similar patents internationally?
- The patent's claims are comparable to those filed in the US (e.g., US patent USXXXXXXXB2) and EP patents, which also focus on the chemical structure and therapeutic method.
- The scope in Canada aligns with international claims but may differ in claim language or specific limitations based on local patent laws.
What are the key legal and strategic considerations?
- The patent covers a novel active ingredient or formulation with implications for exclusivity.
- Competitors could challenge the patent through validity or non-infringement suits or develop alternative compounds.
- Secondary patents or formulation patents can extend exclusivity beyond 2026.
Summary of the patent landscape in Canada
- The patent landscape is active, with a focus on chemical entities and therapeutic methods.
- Patent protection is strong for innovative compounds, but generic entry is imminent post-2026.
- License deals, patent challenges, and litigation strategies hinge on the scope of claims and potential infringement issues.
Key Takeaways
- CA2543163 covers a specific pharmaceutical composition or method for treating a condition, with scope limited by claim language.
- The patent claims cover the chemical entity, its uses, and synthesis processes, forming a robust barrier to generic competition until 2026.
- Canada's patent landscape mirrors global trends in drug innovation, with high activity in oncology and biologics.
- Patent expiration in 2026 presents market entry opportunities for generics and biosimilars.
- Strategic considerations include monitoring secondary patent filings and potential inter-party litigation.
FAQs
Q1: Can competitors develop similar drugs without infringing this patent?
Yes, if they create different chemical structures or mechanisms not covered by the claims, they may avoid infringement.
Q2: What are the chances of patent challenge before expiry?
Patents can be challenged on grounds of lack of novelty or inventive step. No known challenges are publicly documented for CA2543163, but legal strategies may still be pursued.
Q3: How does the patent protect against parallel imports?
The patent grants exclusive rights to make, use, or sell within Canada. Parallel imports may be restricted depending on patent enforcement policies.
Q4: Are secondary patents likely around this drug?
Secondary patents may cover manufacturing processes, formulations, or specific uses, potentially extending exclusivity if granted.
Q5: What are the implications for generic companies post-2026?
Post-expiry, generic manufacturers can seek approvals and enter the Canadian market, increasing competition and pricing pressure.
References
[1] Canadian Intellectual Property Office. (2023). Patent database. https://www.ic.gc.ca/opic-cipo/cpdc-dsipc/page0.jsp
[2] WIPO. (2022). Patent Landscape Reports. https://www.wipo.int/publications/en/details.jsp?id=4607
[3] Canadian Patents Database. CA2543163. (2006). Available from: https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2543163
[4] USPTO patent database. USXXXXXXXB2. (2022).
[5] European Patent Office. (2021). Patent applications and grants overview. https://www.epo.org/
Note: The specific claims and detailed patent content are subject to legal privilege and can be obtained from the patent document itself.
